China Pharma Holdings (CPHI) Receivables - Other (2010 - 2026)

China Pharma Holdings has reported Receivables - Other for 16 years, with the latest figure at $61657.0 in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other rose 57.91% year-over-year to $61657.0; the trailing twelve-month figure through Mar 2026 stood at $61657.0 (up 57.91% YoY), and the FY2025 full-year result was $49261.0, up 62.65% from the prior year.
• Receivables - Other for Q1 2026 stood at $61657.0, up from $49261.0 in the prior quarter.
• The five-year high for Receivables - Other was $1.2 million in Q1 2022, with the low at $28660.0 in Q2 2024.
• Historically, Receivables - Other has averaged $270495.4 across 5 years, with a median of $48361.0 in 2025.
• Annual changes were most pronounced in 2022 — Receivables - Other slumped 97.96% — and 2023, when it soared 442.04%.
• China Pharma Holdings' Receivables - Other stood at $29139.0 in 2022, then soared by 442.04% to $157944.0 in 2023, then tumbled by 80.82% to $30286.0 in 2024, then surged by 62.65% to $49261.0 in 2025, then advanced by 25.16% to $61657.0 in 2026.
• The last three Receivables - Other figures came in at $61657.0 (Q1 2026), $49261.0 (Q4 2025), and $61275.0 (Q3 2025), per Business Quant data.